NIH Reporter #3R01CA263806-05S2

NIH Grant for Research on p38/JNK MAPK Pathways in Cisplatin-Induced Neurotoxicity

This opportunity is a research grant from the National Cancer Institute (NCI), part of the NIH, focused on mitigating cisplatin-induced neurotoxicity in women with ovarian cancer. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Research to be conducted at University of California-Irvine - OEMs and Vendors: - No specific OEMs or commercial vendors are named in the solicitation - Products/Services Requested: - Research services targeting p38 and JNK MAPK pathways - In vitro and in vivo studies - Behavioral analysis - Translational research for therapeutic development - Unique/Notable Requirements: - Emphasis on translational research to develop therapeutics for neurotoxicity mitigation - Focus on adverse nervous system effects of cisplatin in women with ovarian cancer - No specific products, part numbers, or purchase quantities listed - Estimated funding amount: $80,303 - Project duration is approximately two years

Description

This NIH grant opportunity supports research focused on the role of p38 MAPK and JNK pathways in cisplatin-induced neurotoxicity. The project aims to develop therapeutics to mitigate side effects in women with ovarian cancer through in vitro and in vivo studies, behavioral analysis, and translational research. The funding amount is approximately $80,303, with a project duration from July 1, 2025, to June 30, 2027. The research is conducted at the University of California-Irvine under the National Cancer Institute (NCI), part of the NIH.

View original listing